{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:31:21Z","timestamp":1793496681052,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.gim.2025.101557","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:36:22Z","timestamp":1759876582000},"page":"101557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)"],"prefix":"10.1016","volume":"27","author":[{"given":"Joanne","family":"Ngeow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Astiazaran-Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Cass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.F.","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Katcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Klugman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia A.","family":"Livinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta","family":"Voian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra J.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuya","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gim.2025.101557_bib1","doi-asserted-by":"crossref","first-page":"e1526","DOI":"10.1002\/onco.13829","article-title":"Homologous recombination deficiency: cancer predispositions and treatment implications","volume":"26","author":"Toh","year":"2021","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gim.2025.101557_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.gim.2025.101557_bib5","series-title":"GeneReviews","article-title":"Fanconi anemia","author":"Mehta","year":"2002"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101230","article-title":"Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene","volume":"26","author":"Morgan","year":"2024","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"44","key":"10.1016\/j.gim.2025.101557_bib8","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.gim.2025.101557_bib9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of \u223c30,000 cases","volume":"13","author":"Suszynska","year":"2020","journal-title":"J Ovarian Res"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","article-title":"Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility","volume":"21","author":"Rowley","year":"2019","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101243","article-title":"Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Pal","year":"2025","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2","volume":"60","author":"Hanson","year":"2023","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/humu.21625","article-title":"Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients","volume":"33","author":"Thompson","year":"2012","journal-title":"Hum Mutat"},{"issue":"26","key":"10.1016\/j.gim.2025.101557_bib17","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127711","article-title":"Mutation analysis of the RAD51C and RAD51D genes in high-risk ovarian cancer patients and families from the Czech Republic","volume":"10","author":"Janatova","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.gim.2025.101557_bib19","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/ijc.28540","article-title":"About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants","volume":"134","author":"Guti\u00e9rrez-Enr\u00edquez","year":"2014","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.gim.2025.101557_bib20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat Genet"},{"issue":"database issue","key":"10.1016\/j.gim.2025.101557_bib21","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes - Providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/humu.24319","article-title":"A decade of RAD51C and RAD51D germline variants in cancer","volume":"43","author":"Boni","year":"2022","journal-title":"Hum Mutat"},{"issue":"38","key":"10.1016\/j.gim.2025.101557_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202727119","article-title":"Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants","volume":"119","author":"Prakash","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.101036","article-title":"Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance\/Risk Allele Working Group","volume":"26","author":"Schmidt","year":"2024","journal-title":"Genet Med"},{"issue":"23","key":"10.1016\/j.gim.2025.101557_bib27","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMsr1406261","article-title":"ClinGen--the clinical genome resource","volume":"372","author":"Rehm","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib28","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41436-020-0920-4","article-title":"Considerations in assessing germline variant pathogenicity using cosegregation analysis","volume":"22","author":"Belman","year":"2020","journal-title":"Genet Med"},{"issue":"15","key":"10.1016\/j.gim.2025.101557_bib29","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-22-2319","article-title":"Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C","volume":"83","author":"Hu","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","article-title":"The missing diversity in human genetic studies","volume":"177","author":"Sirugo","year":"2019","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41576-020-0255-7","article-title":"Exploring human genomic diversity with gnomAD","volume":"21","author":"Koch","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"34","key":"10.1016\/j.gim.2025.101557_bib32","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","article-title":"Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing","volume":"34","author":"Balma\u00f1a","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gim.2025.101557_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79183","article-title":"BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair","volume":"11","author":"Jimenez-Sainz","year":"2022","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/hmg\/ddac281","article-title":"Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection","volume":"32","author":"Kolinjivadi","year":"2023","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib35","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.3390\/cancers12123771","article-title":"Comprehensive functional characterization and clinical interpretation of 20 splice-site variants of the RAD51C gene","volume":"12","author":"Sanoguera-Miralles","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gim.2025.101557_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.dnarep.2019.02.008","article-title":"RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination","volume":"76","author":"Baldock","year":"2019","journal-title":"DNA Repair (Amst)"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1158\/0008-5472.CAN-19-1991","article-title":"Rare BRIP1 missense alleles confer risk for ovarian and breast cancer","volume":"80","author":"Moyer","year":"2020","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.gim.2025.101557_bib38","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1016\/j.cell.2024.08.039","article-title":"High-resolution functional mapping of RAD51C by saturation genome editing","volume":"187","author":"Olvera-Le\u00f3n","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmedgenet-2018-105872","article-title":"Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report","volume":"56","author":"Spurdle","year":"2019","journal-title":"J Med Genet"},{"key":"10.1016\/j.gim.2025.101557_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/PO.20.00399","article-title":"Impact of variant reclassification in cancer predisposition genes on clinical care","volume":"5","author":"Chiang","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jgc4.1600","article-title":"Characterization of variant reclassification and patient re-contact in a cancer genetics clinic","volume":"31","author":"Muir","year":"2022","journal-title":"J Genet Couns"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41436-019-0478-1","article-title":"Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Deignan","year":"2019","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41431-018-0285-1","article-title":"Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics","volume":"27","author":"Carrieri","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"10.1016\/j.gim.2025.101557_bib44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.gim.2022.05.002","article-title":"Reclassification of clinically-detected sequence variants: framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)","volume":"24","author":"Loong","year":"2022","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib46","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10549-011-1677-x","article-title":"Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility","volume":"130","author":"Vuorela","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.gim.2025.101557_bib47","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1093\/hmg\/ddr229","article-title":"RAD51C is a susceptibility gene for ovarian cancer","volume":"20","author":"Pelttari","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-015-3674-y","article-title":"Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and\/or ovarian cancer","volume":"155","author":"J\u00f8nson","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.gim.2025.101557_bib49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.gim.2025.101557_bib50","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","article-title":"Truncating mutations in the fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles","volume":"38","author":"Seal","year":"2006","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jmedgenet-2015-103529","article-title":"No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing","volume":"53","author":"Easton","year":"2016","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13048-021-00809-w","article-title":"Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing","volume":"14","author":"Cummings","year":"2021","journal-title":"J Ovarian Res"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3589","article-title":"RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families","volume":"15","author":"Schnurbein","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib56","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.annonc.2024.07.244","article-title":"Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing","volume":"35","author":"Rowlands","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","article-title":"The impact of coding germline variants on contralateral breast cancer risk and survival","volume":"110","author":"Morra","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48721","article-title":"Prevalence of germline sequence variations among patients with pancreatic cancer in China","volume":"5","author":"Yin","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib60","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000414","article-title":"Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study","volume":"12","author":"Uson","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1620\/tjem.254.207","article-title":"Intestinal perforation in a patient with colon cancer during treatment with regorafenib: a case report and review of the literature","volume":"254","author":"Ouchi","year":"2021","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib62","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.21037\/jgo.2018.03.11","article-title":"Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation","volume":"9","author":"Palacio","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gim.2025.101557_bib65","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/gcc.23011","article-title":"Survey of germline variants in cancer-associated genes in young adults with colorectal cancer","volume":"61","author":"Mikaeel","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/1940-6207.CAPR-20-0316","article-title":"BRIP1, a gene potentially implicated in familial colorectal cancer type X","volume":"14","author":"Mart\u00edn-Morales","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"issue":"24","key":"10.1016\/j.gim.2025.101557_bib68","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","article-title":"Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma","volume":"26","author":"Yadav","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.gim.2025.101557_bib69","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor Rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"578","key":"10.1016\/j.gim.2025.101557_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7488","article-title":"Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies","volume":"13","author":"Tlemsani","year":"2021","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.gim.2025.101557_bib71","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jmedgenet-2012-100852","article-title":"A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer","volume":"49","author":"Pelttari","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.gim.2025.101557_bib72","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1471-2407-12-552","article-title":"Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients","volume":"12","author":"Pelttari","year":"2012","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2021.279981","article-title":"Genotype-phenotype and outcome associations in patients with fanconi anemia: the National Cancer Institute cohort","volume":"108","author":"Altintas","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib74","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00439-020-02199-3","article-title":"The Human Gene Mutation Database (HGMD\u00ae): optimizing its use in a clinical diagnostic or research setting","volume":"139","author":"Stenson","year":"2020","journal-title":"Hum Genet"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41431-021-00987-7","article-title":"Polygenic risk modeling for prediction of epithelial ovarian cancer risk","volume":"30","author":"Dareng","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib77","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41436-020-0862-x","article-title":"Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants","volume":"22","author":"Barnes","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2025.101557_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073149","article-title":"Realistic expectations are key to realising the benefits of polygenic scores","volume":"380","author":"Sud","year":"2023","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib79","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19084","article-title":"Generalizability of polygenic risk scores for breast cancer among women with European, African, and Latinx ancestry","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gim.2025.101557_bib80","article-title":"Comprehensive breast cancer risk assessment for CHEK2 and ATM pathogenic variant carriers incorporating a polygenic risk score and the Tyrer-Cuzick model","volume":"5","author":"Gallagher","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib81","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1055-9965.EPI-12-1030-T","article-title":"Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer","volume":"22","author":"Pearce","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib82","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jmedgenet-2022-108471","article-title":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence","volume":"59","author":"Lee","year":"2022","journal-title":"J Med Genet"},{"issue":"7","key":"10.1016\/j.gim.2025.101557_bib83","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmedgenet-2021-107904","article-title":"Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors","volume":"59","author":"Lee","year":"2022","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib84","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/jmg-2022-108806","article-title":"Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study","volume":"59","author":"Yang","year":"2022","journal-title":"J Med Genet"},{"issue":"9","key":"10.1016\/j.gim.2025.101557_bib85","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/s41416-024-02851-z","article-title":"Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank","volume":"131","author":"Yang","year":"2024","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-087874","article-title":"Using polygenic risk modification to improve breast cancer prevention: study protocol for the PRiMo multicentre randomised controlled trial","volume":"14","author":"McInerny","year":"2024","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib88","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gim.2025.101557_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2023.11.019","article-title":"Pathogenic germline variants in non-BRCA1\/2 homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival","volume":"180","author":"Kahn","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7811","article-title":"Prevalence of homologous recombination deficiency among patients with germline RAD51C\/D breast or ovarian cancer","volume":"7","author":"Torres-Esquius","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib91","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/jmedgenet-2015-103648","article-title":"Risky business: getting a grip on BRIP","volume":"53","author":"Sopik","year":"2016","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.gim.2025.101557_bib92","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib93","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib94","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib95","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Breast Cancer Association Consortium","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib96","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib97","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","article-title":"Practice bulletin No 182: hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"22","key":"10.1016\/j.gim.2025.101557_bib98","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib99","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.2020190086","article-title":"Radiologic-histopathologic correlation of transvaginal US and risk-reducing salpingo-oophorectomy for women at high risk for tubo-ovarian carcinoma","volume":"2","author":"Sakala","year":"2020","journal-title":"Radiol Imaging Cancer"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/OP.21.00382","article-title":"Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes","volume":"18","author":"Liu","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/igc.0000000000001147","article-title":"Setting the threshold for surgical prevention in women at increased risk of ovarian cancer","volume":"28","author":"Manchanda","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib103","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/AOG.0000000000004732","article-title":"A revised Markov model evaluating oophorectomy at the time of hysterectomy for benign indication: age 65 years revisited","volume":"139","author":"Rush","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib104","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1097\/AOG.0000000000003164","article-title":"774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/ijgc-2020-001541","article-title":"Preventing ovarian cancer through early excision of tubes and late ovarian removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial","volume":"31","author":"Gaba","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.gim.2025.101557_bib106","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.gim.2025.101557_bib107","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib108","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4132\/jptm.2016.06.17","article-title":"Comparison of the classical method and SEE-FIM protocol in detecting microscopic lesions in fallopian tubes with gynecological lesions","volume":"52","author":"Koc","year":"2018","journal-title":"J Pathol Transl Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101557_bib109","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.gim.2025.101557_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.03.017","article-title":"Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes","volume":"173","author":"Schwartz","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"suppl 2","key":"10.1016\/j.gim.2025.101557_bib111","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.acra.2023.01.007","article-title":"Interval breast cancers versus screen detected breast cancers: a retrospective cohort study","volume":"30","author":"Ambinder","year":"2023","journal-title":"Acad Radiol"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib112","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1078-0432.CCR-15-0459","article-title":"Triple-negative versus non-triple-negative breast cancers in high-risk women: phenotype features and survival from the HIBCRIT-1 MRI-including screening study","volume":"22","author":"Podo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib113","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3595","article-title":"Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain","volume":"16","author":"Domingo","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab044","article-title":"Penetrance of breast cancer susceptibility genes from the eMERGE III Network","volume":"5","author":"Fan","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13058-021-01400-3","article-title":"Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016","volume":"23","author":"Ramin","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib116","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib117","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor Rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.gim.2025.101557_bib118","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial","volume":"7","author":"Pujade-Lauraine","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib120","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/annonc\/mdy338","article-title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1\/2-negative breast cancers","volume":"29","author":"Chen","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib121","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1186\/s12885-022-10456-z","article-title":"Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations","volume":"22","author":"Yao","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.gim.2025.101557_bib122","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.gim.2025.101557_bib123","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from Rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"O\u2019Malley","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.gim.2025.101557_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100866","article-title":"ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Miller","year":"2023","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2025.101557_bib125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41523-021-00360-3","article-title":"Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing","volume":"7","author":"Southey","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.gim.2025.101557_bib127","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41436-021-01203-z","article-title":"Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Gregg","year":"2021","journal-title":"Genet Med"},{"issue":"13","key":"10.1016\/j.gim.2025.101557_bib128","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/1471-0528.17571","article-title":"Prenatal and pre-implantation genetic testing for monogenic disorders for germline cancer susceptibility gene variants: UK joint consensus guidance","volume":"130","author":"Wafik","year":"2023","journal-title":"BJOG"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:28:09Z","timestamp":1793496489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360025002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":125,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1098360025002047"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101557","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101557"}}